# Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

> **NCT07243691** · NA · RECRUITING · sponsor: **Sir Run Run Shaw Hospital** · enrollment: 33 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Tislelizumab: 200mg, intravenous infusion, Q3W

## Key facts

- **NCT ID:** NCT07243691
- **Lead sponsor:** Sir Run Run Shaw Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-12-15
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07243691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07243691, "Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07243691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*